Posted in M&A / Deals Eli Lilly doubles down on in vivo with $7bn Kelonia buyout April 21, 2026 Pharmaceutical Technology Lilly now has a lentiviral and LNP-based platform for in vivo delivery under its belt, which could broaden the company’s chance of success. M&A / DealsGene Therapy PlatformRead full story